At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France, discusses AURELIA, an open-label, randomised, phase 3 clinical trial that was designed to evaluate bevacizumab combined with chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel or topotecan) for patients with platinum-resistant recurrent ovarian cancer.
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
9th December 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?